POLITICS

US advances first government-funded trials of psychedelic drug ibogaine

PUBLISHED Oct 5, 2026, 11:43 AM ET

Read, Watch or Listen

US advances first government-funded trials of psychedelic drug ibogaine

Media Bias Meter

Sources: 24

Left 13%

Center 75%

Right 13%

Sources: 24

The United States Food and Drug Administration is advancing government-funded clinical trials investigating the psychedelic drug ibogaine to treat opioid addiction and post-traumatic stress disorder. Health officials opened a public docket seeking feedback on trial design, safety monitoring, patient eligibility, and dosage limits following an executive order. Ibogaine, derived from the African iboga shrub, remains classified as an illegal Schedule I controlled substance under federal law due to severe health risks including cardiac arrhythmias. Federal health agencies including the National Institute on Drug Abuse are funding early-stage research through the Advanced Research Projects Agency for Health. Initial trial protocols propose single gradual doses capped at ten milligrams per kilogram alongside continuous hospital heart monitoring for up to thirty-six hours. The regulatory push responds to growing interest from military veterans seeking relief from treatment-resistant trauma and substance abuse disorders through rigorous scientific evaluation.

By Noormahi M. | JQJO News

Timeline of Events

On April 2026 President Donald Trump signed executive order funding ibogaine research.
On May 2026 federal agencies announced plans for early-stage clinical trial development.
On June 2026 researchers outlined initial safety parameters and patient screening guidelines.
On July 2026 health officials reviewed cardiac risks associated with psychedelic compounds.
On August 2026 regulatory bodies prepared formal frameworks for public safety comment.
On September 2026 the Food and Drug Administration opened public comment dockets.
On October 2 2026 health officials advanced the first government-funded clinical trials.
On October 3 2026 medical experts discussed continuous cardiac monitoring protocols during trials.
On October 4 2026 veterans advocacy groups praised federal investment in alternative therapies.
On October 5 2026 regulators evaluated public feedback regarding participant safety and dosing.
On November 20 2026 Researchers will review submitted public safety commentary after the deadline.
On January 1 2027 Agencies will approve final clinical trial protocols for human testing phases.

News Intelligence

Immediate US impact: Federal funding accelerates alternative treatments for treatment-resistant opioid addiction.
Possible long-term US impact: Standardized safety protocols could establish federal pathways for psychedelic medicine.
Most affected groups: Military veterans, addiction patients, federal health agencies, and pharmaceutical researchers.
Reader priority: Monitor official regulatory notices and peer-reviewed medical research updates closely.

Media Bias

Articles Published:: 24
Right Leaning:: 3
Left Leaning:: 3
Neutral:: 18
Distribution:: Left 13%, Center 75%, Right 13%

Explain Framing

Left: Emphasizes strict safety protocols and severe cardiac health risks. Center: Focuses objectively on regulatory processes and federal research funding. Right: Highlights executive leadership and treatments for military veterans.